Human mesenchymal stem cells derived from adipose tissue reduce functional and tissue damage in a rat model of chronic renal failure

Simple item page
dc.contributor.authorVillanueva, Sandra
dc.contributor.authorCarreno, Juan E.
dc.contributor.authorSalazar, Lorena
dc.contributor.authorVergara, Cesar
dc.contributor.authorStrodthoff, Rocio
dc.contributor.authorFajre, Francisca
dc.contributor.authorCespedes, Carlos
dc.contributor.authorSaez, Pablo J.
dc.contributor.authorIrarrazabal, Carlos
dc.contributor.authorBartolucci, Jorge
dc.contributor.authorFigueroa, Fernando
dc.contributor.authorVio, Carlos P.
dc.date.accessioned2025-01-24T00:09:24Z
dc.date.available2025-01-24T00:09:24Z
dc.date.issued2013
dc.description.abstractTherapeutic approaches for CKD (chronic kidney disease) have been able to reduce proteinuria, but not diminish the disease progression. We have demonstrated beneficial effects by injection of BM (bone marrow)-derived MSCs (mesenchymal stem cells) from healthy donors in a rat model with CKD. However, it has recently been reported that BM-MSCs derived from uraemic patients failed to confer functional protection in a similar model. This suggests that autologous BM-MSCs are not suitable for the treatment of CKD. In the present study, we have explored the potential of MSCs derived from adipose tissue (AD-MSCs) as an alternative source of MSCs for the treatment of CKD. We have isolated AD-MSCs and evaluated their effect on the progression of CKD. Adult male SD (Sprague Dawley) rats subjected to 5/6 NPX (nephrectomy) received a single intravenous infusion of 0.5 x 10(6) AD-MSCs or MSC culture medium alone. The therapeutic effect was evaluated by plasma creatinine measurement, structural analysis and angiogenic/epitheliogenic protein expression. AD-MSCs were detected in kidney tissues from NPX animals. This group had a significant reduction in plasma creatinine levels and a lower expression of damage markers ED-1 and alpha-SMA (alpha-smooth muscle actin) (P < 0.05). In addition, treated rats exhibited a higher level of epitheliogenic [Pax-2 and BMP-7 (bone morphogenetic protein 7)] and angiogenic [VEGF (vascular endothelial growth factor)] proteins. The expression of these biomarkers of regeneration was significantly related to the improvement in renal function. Although many aspects of the cell therapy for CKD remain to be investigated, we provide evidence that AD-MSCs, a less invasive and highly available source of MSCs, exert an important therapeutic effect in this pathology.
dc.fuente.origenWOS
dc.identifier.doi10.1042/CS20120644
dc.identifier.issn0143-5221
dc.identifier.urihttps://doi.org/10.1042/CS20120644
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/101989
dc.identifier.wosidWOS:000321029800009
dc.issue.numero3-4
dc.language.isoen
dc.pagina.final210
dc.pagina.inicio199
dc.revistaClinical science
dc.rightsacceso restringido
dc.subjectadipose-tissue-derived mesenchymal stem cell
dc.subjectchronic kidney disease
dc.subjectnephrectomy
dc.subjectproteinuria
dc.subjectrenal functional recovery
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleHuman mesenchymal stem cells derived from adipose tissue reduce functional and tissue damage in a rat model of chronic renal failure
dc.typeartículo
dc.volumen125
sipa.indexWOS
sipa.trazabilidadWOS;2025-01-12
Files
Collections
Artículos de revistas